Lapatinib Ditosylate Hydrate

二甲苯磺酸拉帕替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLapatinib Ditosylate Hydrate
Drug Alias NameLapatinib ditosilate二对甲苯磺酸拉帕替尼Cipatinib拉帕替尼二对甲苯磺酸盐水合物Tycerb +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerCNS Embryonal Tumor +[62] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2007/03/13
Country/TerritoryCzechiaBelgiumBulgaria +[54] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline PlcNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline AgGlaxosmithkline PlcNovartis Pharma Ag +[9] 
Inactive CompaniesUniversity Of California San FranciscoGeorgetown UniversityUniversity of Zurich +[19] 
Active IndicationsBrain metastasesBreast Neoplasms
Inactive IndicationsMetastatic breast cancerCNS Embryonal TumorGastroesophageal Junction Neoplasms +[60] 

Other Information

ATC CodeL01EH01
Related LinksWikipediaDrugBankKEGG